Chromatin-Immunoprecipitation is the key experimental approach to locate histone modifications and transcription factors in the genome, yet for robust and automatized detection this assay requires large numbers of cells. A key objective of BLUEPRINT is to reduce the number of cells required as input for one ChIP-seq profile aiming at less then 5000 cells per profile. This is particularly important for the analysis of cells that are rare, e.g. the HSC or clinical samples of cells that are obtained by small volume needle biopsies, e.g. in case of solid organ cancers.
We are looking for a novel academic or SME partner to strengthen our Work Package 13 ‘Technology optimization for microscale application’. The new BLUEPRINT partner should have an operational analysis pipeline or will have such a pipeline up and running by the end of 2013. To this end, we expect applicants to have proof of concept data. The analysis pipeline should encompass pre- and post-chip sample preparation, the end product being a library ready for Illumina Next Gen Sequencing.
PLEASE NOTE: DEADLINE FOR SUBMISSION OF APPLICATIONS IS POSTPONED UNTILL 21 FEBRUARY 2013, 17h00